Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director
-
NurExone Biologic Secures Master Cell Bank - a Key Milestone for Therapeutic Exosome Production
-
NurExone announces significant findings from a preclinical study of the potential of its portfolio drug, ExoPTEN, for repairing Optic Nerve Damage (OND)
-
NurExone Reports Third Quarter 2024 Financial Results and Provides Corporate Update
-
European Medicines Agency Awards Orphan Status to NurExone's ExoPTEN for Spinal Cord Injury, Paving the Way to European Market Entry
-
Company reports Q3 2024 XHANCE net revenue of $20.4 million, an increase of 3% compared to Q3 2023 Company reports positive inflection in new prescriptions of XHANCE starting in September Company...
-
NurExone Biologic Closes Final Tranche of Non-Brokered Private Placement and Provides Corporate Update
-
MIAMI, Oct. 31, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces NRx Pharmaceuticals (NASDAQ: NRXP) will appear on the Emerging Growth Conference...
-
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024
-
NurExone’s Groundbreaking Exosome Therapies to be Showcased at Fall U.S. Conferences